For the Inventor, By the Inventor

Enter assignee name

Development Center for Biotechnology

Calculating rank

USPTO Granted Patents = 97

CIPO Patents = 6

EPO Patents = 18

Forward Citations = 262

Loading Chart...

Loading Chart...

302 inventors (with patents filed for the assignee):

Rey-Yuh Wu (10 out of 11 patents)

Chu-Bin Liao (9 out of 9 patents)

Ta-Tung Yuan (8 out of 8 patents)

4. Shyh-Fong Chen (8 out of 9 patents)

5. Shih-Hsien Chuang (7 out of 18 patents)

6. Mann-Yan Kuo (7 out of 7 patents)

7. Yu-Yuan Wu (7 out of 50 patents)

8. Szu-Liang Lai (6 out of 6 patents)

9. Shih-Chong Tsai (6 out of 6 patents)

10. Yuh-Shan Chung (6 out of 6 patents)

11. Hsin Tsai (6 out of 6 patents)

12. Chih-Yung Hu (5 out of 5 patents)

13. Chao-Yang Huang (5 out of 8 patents)

14. Ying-Yung Lok (5 out of 5 patents)

15. Shao-Zheng Peng (5 out of 5 patents)

Core Competencies:

Antibody-Drug Conjugates

Anti-CD73

Anti-PD-L1

Heterocyclic Compounds

Tyrosine Kinase Inhibitors

Glycoprotein Conjugates

Cancer Therapy

Neurotensin Receptor

Modulators

Plant Extracts

Immunotherapy

Kinase Inhibitors

97 patents: Sort by Forward Citations

1. 12767717 - ANTI-HUMAN PD-L1 ANTIBODIES AND THEIR USES (2026-10-20),

2. 12448394 - Heterocyclic pyrazole derivatives as type III receptor tyrosine kinase inhibitors (2025-10-21),

3. 12202899 - Anti-human PD-L1 antibodies and their uses (2025-01-21),

4. 12187806 - Anti-CD73 antibodies and use thereof (2025-01-07),

5. 12091454 - Humanized anti-human neurotensin receptor 1 antibodies and their uses (2024-09-17),

6. 12043668 - Anti-human CSF-1R antibody and uses thereof (2024-07-23),

7. 11998613 - Antibody-drug conjugates containing an anti-mesothelin antibody and uses thereof (2024-06-04),

8. 11499139 - Targeted integration sites in Chinese hamster ovary cell genome (2022-11-15),

9. 11407757 - Heterocycle compounds as Tyro3, Axl and MerTK (TAM) family of receptor tyrosine kinase inhibitors (2022-08-09),

10. 11384150 - Antibody-drug conjugates and uses thereof (2022-07-12),

11. 11085062 - Processes for preparing glycoprotein-drug conjugates (2021-08-10),

12. 10980853 - Process for preparing a crassocephalum crepidioides extract, extract prepared thereby and use of the extract (2021-04-20),

13. 10947316 - Antibody-drug conjugates containing anti-Globo H antibodies and uses thereof (2021-03-16),

14. 10793542 - Hetroarylamine compounds for modulating the hedgehog pathway and preparing method and uses thereof (2020-10-06),

15. 10781266 - Antibodies specific to alpha-enolase and uses thereof (2020-09-22),

Company Overview

The Development Center for Biotechnology, located in Taipei, Taiwan, specializes in advancing antibody therapeutics with a focus on innovative cancer therapies. The organization is engaged in the research and development of antibody-drug conjugates and various monoclonal antibodies, including anti-CD73 and anti-PD-L1, aimed at enhancing treatment efficacy. Additionally, it explores heterocyclic compounds and tyrosine kinase inhibitors, contributing to the broader field of biopharmaceuticals and targeted therapies.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

97 Patents

#38 in Taipei

#242 in Taiwan

#8,004 in the World

Development Center for Biotechnology

Forward Citations = 262

302 inventors:

Rey-Yuh Wu (10 out of 11 patents)

Chu-Bin Liao (9 out of 9 patents)

Ta-Tung Yuan (8 out of 8 patents)

4. Shyh-Fong Chen (8 out of 9 patents)

5. Shih-Hsien Chuang (7 out of 18 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Development Center for Biotechnology. Retrieved from https://idiyas.com/company/development-center-for-biotechnology

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…